Portola Pharmaceuticals Inc (NASDAQ:PTLA) – Investment analysts at Oppenheimer lowered their FY2018 EPS estimates for shares of Portola Pharmaceuticals in a research note issued on Tuesday. Oppenheimer analyst J. Olson now expects that the biopharmaceutical company will post earnings of ($4.86) per share for the year, down from their prior forecast of ($4.81). Oppenheimer currently has a “Buy” rating and a $72.00 target price on the stock. Oppenheimer also issued estimates for Portola Pharmaceuticals’ FY2019 earnings at ($0.47) EPS, FY2020 earnings at $2.82 EPS, FY2021 earnings at $4.46 EPS and FY2022 earnings at $6.37 EPS.
Several other research firms have also commented on PTLA. BidaskClub upgraded shares of Portola Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. ValuEngine upgraded shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Goldman Sachs Group began coverage on shares of Portola Pharmaceuticals in a research report on Friday, December 1st. They set a “buy” rating and a $75.00 price target on the stock. Finally, William Blair restated a “buy” rating on shares of Portola Pharmaceuticals in a research report on Monday, January 1st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $65.52.
Shares of Portola Pharmaceuticals (NASDAQ:PTLA) opened at $45.82 on Friday. The company has a market cap of $2,937.62, a price-to-earnings ratio of -10.61 and a beta of 1.18. The company has a current ratio of 8.31, a quick ratio of 8.31 and a debt-to-equity ratio of 0.24. Portola Pharmaceuticals has a 52-week low of $29.50 and a 52-week high of $67.10.
In other Portola Pharmaceuticals news, Director Henry Ward Wolff sold 12,000 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $47.00, for a total transaction of $564,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 5.50% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of PTLA. Ameriprise Financial Inc. purchased a new position in Portola Pharmaceuticals during the second quarter valued at $1,762,000. Parametric Portfolio Associates LLC lifted its holdings in Portola Pharmaceuticals by 11.0% during the second quarter. Parametric Portfolio Associates LLC now owns 35,675 shares of the biopharmaceutical company’s stock valued at $2,004,000 after purchasing an additional 3,530 shares in the last quarter. QS Investors LLC purchased a new position in Portola Pharmaceuticals during the second quarter valued at $147,000. Raymond James Financial Services Advisors Inc. purchased a new position in Portola Pharmaceuticals during the second quarter valued at $248,000. Finally, Fisher Asset Management LLC lifted its holdings in Portola Pharmaceuticals by 32.7% during the third quarter. Fisher Asset Management LLC now owns 61,893 shares of the biopharmaceutical company’s stock valued at $3,344,000 after purchasing an additional 15,256 shares in the last quarter. 86.45% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This story was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://transcriptdaily.com/2018/02/25/portola-pharmaceuticals-inc-expected-to-earn-fy2018-earnings-of-4-86-per-share-ptla.html.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.